ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0874

A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out
Abstract Number: 0225

A Transitions Retreat: Preparing Rheumatology Fellows for Career Planning and the Scholarly Phase of Training
Abstract Number: 0878

A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old
Abstract Number: 0218

A Web-based Education Program Improves Health Care Provider Knowledge for the Care of Cancer Patients Receiving Immunotherapy Who Develop Rheumatic Immune-related Complications, and Those with Pre-existing Rheumatic Disease: An Initiative of CanRIO
Abstract Number: 1095

A20(Tnfaip3) in Keratinocytes Restricts an Early Antiviral Gene Program Associated with Psoriatic Skin and Joint Disease
Abstract Number: 1370

Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
Abstract Number: 0530

Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)
Abstract Number: 0397

Aberrant Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis
Abstract Number: 1108

Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis
Abstract Number: 2044

Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome
Abstract Number: 2226

Accelerated Aging Based on Blood DNA Methylation in SLE Participants Compared to Healthy Controls
Abstract Number: 0932

Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs
Abstract Number: 0057

Accelerating AxSpA Diagnosis: Exploring At-home Self-sampling, Symptom Checkers, Medical Student-visits and Asynchronous Report-based Assessment
Abstract Number: 0195

Acceptance of Virtual Reality for Managing Their Disease Among People with Rheumatologic Conditions with and Without Prior Experience Using Virtual Reality
Abstract Number: 0751

Accessing Telehealth and In-Person Healthcare During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis

« Previous Page
1
…
3
4
5
6
7
…
154
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].